CRISPR Therapeutics AG (CRSP) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines using CRISPR-Cas9. Its most advanced achievement is Casgevy, an approved therapy for sickle cell disease and transfusion-dependent beta thalassemia developed with Vertex Pharmaceuticals, which edits a patient's own blood stem cells. The broader pipeline extends to allogeneic cell therapies for cancer, in vivo editing for cardiovascular and other diseases, and type 1 diabetes programmes.
How CRISPR Therapeutics Makes Money
Revenue is currently limited, consisting of collaboration payments and a share of Casgevy economics under the Vertex partnership, where Vertex leads commercialisation. The company funds a broad pipeline from its cash balance and collaboration income. The investment case rests on Casgevy's commercial ramp and on pipeline programmes, particularly in vivo editing, which would avoid the complex cell-extraction-and-reinfusion process that limits current therapies.
CRISPR Therapeutics Revenue & Profitability Breakdown
This chart shows how CRISPR Therapeutics's revenue flows through to profit. As a financial-sector company, CRISPR Therapeutics doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.
Key Financial Metrics
CRISPR Therapeutics AG doesn't carry a meaningful trailing P/E right now, generates $-215.8M in free cash flow, runs a debt/equity ratio of 44.87, and converts shareholder equity into profit at a -26.1% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering CRISPR Therapeutics AG currently haven't converged on a clear consensus rating, with a mean 12-month price target of $87.56. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Technical Price Signals
CRSP is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
CRSP Investment Case: Bull vs Bear
CRSP's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Casgevy is an approved, potentially curative gene-editing therapy — a landmark that validates the underlying platform clinically and regulatorily.
- In vivo gene editing, delivered directly into the body, would remove the logistical complexity that constrains current cell-based therapies.
- The Vertex partnership provides commercial capability and cost sharing that CRISPR could not build alone.
- A substantial cash balance funds pipeline development for a meaningful period without immediate financing pressure.
Bear Case (Key Risks)
- Casgevy's commercial ramp has been slow — the treatment process is complex, requires specialised centres, and involves conditioning chemotherapy patients may decline.
- Very high therapy pricing creates payer resistance and lengthy reimbursement negotiations, particularly in public health systems.
- Competing gene editing approaches, including base editing, may prove safer or more precise than the Cas9 nuclease approach.
- Pipeline programmes beyond Casgevy are early, so clinical setbacks would remove much of the forward valuation.
What to Watch: CRSP Key Metrics
CRSP Stock — Frequently Asked Questions
Compare CRSP with Peers
More Healthcare Stock Analysis
In-depth reports on companies operating alongside CRSP — business models, bull and bear cases, and the metrics that matter.
Unlock the Full CRSP Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.